U.S. stock night trading volatility: Verrica private placement financing of $50 million, stock price soars 7.23% in night trading

U.S. Stock Night Market Movements

Verrica rose 7.23% in the night market. Based on recent key news:

1. On November 24, Verrica Pharmaceuticals announced a $50 million private placement to repay debt and extend cash flow. This move enhanced the company's financial stability, driving the stock price up. Source: Reuters

2. On November 25, Verrica Pharmaceuticals signed a securities purchase agreement with institutional investors, planning to sell 6.5 million shares. This news further boosted market confidence, and the stock price continued to rise. Source: SEC announcement

3. On November 25, despite the financing being highly dilutive to shareholders, the company's strategic advantages were evident through debt elimination and extended operational time. Analysts maintained a hold rating, and the stock price rose as a result. Source: TR | OpenAI – 4o Analysis Report on recent financing activities in the biopharmaceutical industry.

Stocks with High Trading Volume in the Industry

Eli Lilly rose 0.10% in the night market. Based on recent key news:

1. On November 21, Eli Lilly's market capitalization surpassed $1 trillion, becoming the first pharmaceutical company in the world to reach a trillion-dollar market cap. The stock price increase was mainly due to the strong sales of the weight loss drug tirzepatide, with significant sales growth for Mounjaro and Zepbound. Source: Zhitong Finance

2. On November 24, Morgan Stanley and Bernstein raised their target prices for Eli Lilly, reflecting market optimism about its future growth. Morgan Stanley raised the target price to $1,290, while Bernstein raised it to $1,300. Source: Morgan Stanley, Bernstein

3. On November 25, Novo Nordisk's trial results for semaglutide were disappointing, failing to significantly slow the progression of Alzheimer's disease, leading to a drop in its stock price, while Eli Lilly's stock price continued to strengthen. Source: Morgan Stanley analyst report indicating strong demand in the pharmaceutical industry and noticeable capital inflows.

Novo Nordisk rose 0.32% in the night market. Based on recent key news:

1. On November 24, Novo Nordisk announced that semaglutide failed to delay the progression of Alzheimer's disease, causing its stock price to plummet to the lowest level since 2021. Following the announcement, the stock price fell by as much as 12.4% in Copenhagen trading, reflecting investor concerns about the company's long-term competitiveness in the obesity treatment market. Source: Zhitong Finance

2. On November 24, HSBC downgraded Novo Nordisk's rating from "Buy" to "Hold," lowering the target price from 445 Danish kroner to 300 Danish kroner. The downgrade further intensified stock price pressure. Source: Jinshi Data

3. On November 25, Sydbank analysts believed that Novo Nordisk's stock price plunge was an overreaction by the market, possibly influenced by recent negative sentiment and news. Source: CNBC indicating increased competition and risks in the obesity market Pfizer fell 0.04% in after-hours trading. Based on recent key news:

4. On November 26, the U.S. government reached a price reduction agreement with pharmaceutical companies regarding Pfizer's breast cancer treatment drug Ibrance, which is expected to significantly lower drug costs and impact Pfizer's stock price. Source: Jin10 Data

5. On November 25, Guggenheim raised Pfizer's target price to $35 and maintained a "Buy" rating, reflecting market confidence in its future performance. Source: The Wall Street Journal

6. On November 24, analysts rated Pfizer as "Hold," believing that five other stocks have more investment value, affecting market enthusiasm for investing in Pfizer. Source: MarketBeat The pharmaceutical industry is driven by innovation, with significant capital inflows